The FDA approved a novel new treatment for the most common kind of skin cancer. The drug is called Erivedge (vismodegib) and treats patients with basal cell carcinoma. The drug is intended for use in people with locally advanced basal cell cancer who are not candidates for surgery or radiation and when cancer has spread to other parts of the body (is metastatic).
Some interesting points about Erivedge, is that it was reviewed under the FDA priority review program. This usually means that the agency recognizes that the drug is a novel approach to an important condition, that there are few other treatment options or some combination of atributes.
Ongoing research will reveal the true benefits and risks and you can find more information atwww.fda.gov.